Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Opus Genetics Inc.

An update from Rocket Doctor AI ( ($TSE:AIDR) ) is now available. Rocket Doctor AI has launched patient care operations in Maryland through its who...

Rocket Doctor AI Expands Into Maryland, Names New Medical Lead to Drive U.S. Growth

An update from Bird Construction ( ($TSE:BDT) ) is now available. Bird Construction Inc. said it will release its 2026 first-quarter financial resu...

Bird Construction Sets May 13 Release, May 14 Call for Q1 2026 Results

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurosense Therapeutics Ltd. (NRSN) and Opus Genetic...

Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Opus Genetics (IRD)

Opus Genetics ( ($IRD) ) just unveiled an update. On April 2, 2026, Opus Genetics entered into a senior secured note purchase agreement providing a...

Opus Genetics Secures Major Non-Dilutive Funding Facility

Investors will find the hottest stock market stories ready to go in our daily wrap-up for Thursday.


Morning News Wrap-Up 4/2/26: Today’s Biggest Stock Market Stories!

In a report released on March 18, Kevin Roger from Kepler Capital maintained a Buy rating on Viridien, with a price target of €180.00. The company’...

Kepler Capital  Remains a Buy on Viridien (0RI9)

An update from Rocket Doctor AI ( ($TSE:AIDR) ) is now available. Rocket Doctor AI Inc., a Vancouver-based provider of AI-powered healthcare techno...

Rocket Doctor AI Raises $2.05 Million from Warrant Exercises to Fund AI Health Expansion

In a report released today, Krista Friesen from CIBC maintained a Buy rating on Bird Construction, with a price target of C$40.00. Friesen covers t...

Bird Construction (BDT) Receives a Buy from CIBC

Viatris, Inc. ($VTRS), Opus Genetics, Inc. ($IRD) announced an update on their ongoing clinical study. The study, officially titled “Randomized, Pl...

Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst

Opus Genetics, Inc. ($IRD) announced an update on their ongoing clinical study. The Phase 3 study “Randomized, Double-masked, Placebo-controlled, M...

Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch

Bird Construction ( ($TSE:BDT) ) has provided an update. Bird Construction reported flat 2025 annual revenue of $3.40 billion versus 2024 but a sha...

Bird Construction Builds Record $11 Billion Backlog as 2025 Profit Hit by One-Time Impairment

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ironwood Pharma (IRWD – Research Report) and Opus Ge...

Analysts Offer Insights on Healthcare Companies: Ironwood Pharma (IRWD) and Opus Genetics (IRD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Opus Genetics (IRD – Research Report) and ImageneBio...

Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA)

Rocket Doctor AI ( ($TSE:AIDR) ) has issued an update. Rocket Doctor AI Inc. has expanded its New York presence by securing an additional in-networ...

Rocket Doctor AI Widens New York Medicare Reach With New In-Network Insurer Deal

On Tuesday, March 10,&nbsp;Oracle ($ORCL), Allbirds ($BIRD), and Kohl’s ($KSS) will report their earnings. Kohl’s will report before the market ope...

Market Cap	$124.01M	P/E Ratio	N/A
52W High	$5.30	52W Low	$0.65
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	17.4%	52W Position	95.5%
Overall Score	43	Value Score	40
Quality Score	31	Technical Score	58

EPS Current Est	$-0.53	EPS Next Est	$-0.56
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IRD	$5.09	+3.46%	621.82K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IRD	$5.09	+3.5%	621.82K
3
4
5
6

IRD

IRD

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Opus Genetics Inc. Data in Excel

Get Opus Genetics Inc. Data in Excel